BeauBrain Healthcare
BeauBrain Healthcare develops AI-based tools and digital therapeutics for early detection, risk prediction, and prevention of Alzheimer’s disease. The company focuses on quantitative neuroimaging (PET/CT and 2D MRI), tablet- and mobile-based cognitive assessment and training, clinical validation through published studies, and integration of imaging with genomic and cognitive data to enable precision brain-health services.
Industries
Nr. of Employees
small (1-50)
Patents
Virtual reality device for diagnosis of nerve disorder, system and method for thereof
US-11317849-B2
View Details
Virtual reality device for diagnosis of nerve disorder, system and method for thereof
US-11317849-B2
View DetailsProducts
Amyloid PET quantification software (PET/CT)
Software tool for automated regional quantification of amyloid PET scans, reporting standardized metrics to aid diagnosis and staging.
2D MRI atrophy analysis and biomarker prediction software
Deep-learning based software that quantifies atrophy from 2D MRI and predicts biomarker positivity (amyloid/tau), brain age, and dementia risk scores.
Tablet-based cognitive screening solution
Digital cognitive screening application for tablets covering multiple cognitive domains for clinical screening and monitoring.
Mobile cognitive training app and managed program
Mobile trainer for multi-domain cognitive exercises with gamification, clinician management, and group activities for prevention and rehabilitation.
Amyloid PET quantification software (PET/CT)
Software tool for automated regional quantification of amyloid PET scans, reporting standardized metrics to aid diagnosis and staging.
2D MRI atrophy analysis and biomarker prediction software
Deep-learning based software that quantifies atrophy from 2D MRI and predicts biomarker positivity (amyloid/tau), brain age, and dementia risk scores.
Tablet-based cognitive screening solution
Digital cognitive screening application for tablets covering multiple cognitive domains for clinical screening and monitoring.
Mobile cognitive training app and managed program
Mobile trainer for multi-domain cognitive exercises with gamification, clinician management, and group activities for prevention and rehabilitation.
Services
Analytical service that quantifies regional amyloid burden from PET/CT images and reports standardized metrics for clinical interpretation.
Software analysis of routine 2D MRI to quantify regional atrophy and predict biomarker positivity, dementia risk indices, brain age, and prognosis.
Implementation and support for a tablet computer-based cognitive screening test evaluating multiple cognitive domains for screening and monitoring.
Mobile app-based cognitive training programs with clinician-managed options (1:1 neuropsychologist support), group activities, and home-based regimens aimed at prevention and cognitive improvement.
Conducting and supporting clinical studies, RCTs, and publications to validate digital assessments and cognitive training interventions.
Analytical service that quantifies regional amyloid burden from PET/CT images and reports standardized metrics for clinical interpretation.
Software analysis of routine 2D MRI to quantify regional atrophy and predict biomarker positivity, dementia risk indices, brain age, and prognosis.
Implementation and support for a tablet computer-based cognitive screening test evaluating multiple cognitive domains for screening and monitoring.
Mobile app-based cognitive training programs with clinician-managed options (1:1 neuropsychologist support), group activities, and home-based regimens aimed at prevention and cognitive improvement.
Conducting and supporting clinical studies, RCTs, and publications to validate digital assessments and cognitive training interventions.
Expertise Areas
- Neuroimaging analysis for Alzheimer’s biomarkers
- AI/ML for medical image quantification
- Digital cognitive assessment and screening
- Mobile digital therapeutics for cognitive training
Key Technologies
- Deep learning for image analysis
- Ensemble machine learning
- PET quantification metrics (SUVR, Centiloid)
- 2D MRI atrophy quantification
News & Updates
Exhibition and promotion of imaging analysis software, MRI-based risk prediction, tablet cognitive test, and cognitive training app at national health tech events.
Presented AI-based amyloid PET image analysis solution at a dementia-focused international scientific meeting.
Company statements and media coverage on plans to pursue U.S. market expansion and potential establishment of a U.S. subsidiary.
Announcement of selection to participate in a digital health industry matching event focusing on AI transition in digital health.
Received national regulator (MFDS) Class 2 certification for an AI-based amyloid PET/CT image analysis software solution.
Completed a Series A financing round to support product expansion into clinical settings and health screening centers (reported in press coverage).
Exhibition and promotion of imaging analysis software, MRI-based risk prediction, tablet cognitive test, and cognitive training app at national health tech events.
Presented AI-based amyloid PET image analysis solution at a dementia-focused international scientific meeting.
Company statements and media coverage on plans to pursue U.S. market expansion and potential establishment of a U.S. subsidiary.
Announcement of selection to participate in a digital health industry matching event focusing on AI transition in digital health.
Received national regulator (MFDS) Class 2 certification for an AI-based amyloid PET/CT image analysis software solution.
Completed a Series A financing round to support product expansion into clinical settings and health screening centers (reported in press coverage).